Eating Disorders News and Research

Latest Eating Disorders News and Research

School to college transition can trigger eating disorders in young adults

Research shows that the transition to college, with its inherent pressures and changes, can increase the likelihood of eating disorders in young adults. While college students are empowered with newfound independence, this freedom can also trigger unhealthy and dangerous behaviors.

27 Oct 2009

Rates of binge eating among adult women identical across race but not among college age women

Existing research shows that rates of binge eating among adult women is virtually identical across race. However, among college age women, it's a different story: Caucasian women are more apt to exhibit binge eating behaviors than African American women, according to a study presented at this month's annual scientific meeting of the Obesity Society.

26 Oct 2009

Study compares differences between inpatient and day treatment of bulimia nervosa

A German study published in the fifth issue of Psychotherapy and Psychosomatics compares the differences between inpatient and day treatment of bulimia nervosa.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

VitalRemedyMD, a physician-established company, offers scientifically formulated integrative nutritional supplements designed to improve the quality of traditional healthcare. "We are proud that VitalProteinRx is now an integral part of Fresenius' armamentarium in helping patients with chronic kidney disease," stated Dr. Seth Baum, Founder of VitalRemedyMD.

13 Oct 2009

Cognitive behavioral therapy effective for bulimia and binge eating disorders

Although most people with bulimia and binge eating disorders wait many years before seeking help, a new review shows that psychological treatment can make a large difference — and that cognitive behavioral therapy (CBT) is the most effective talk therapy for these disorders.

6 Oct 2009

Eating Recovery Center expands inpatient facilites to meet increased demand

Answering increasing demand for specialized treatment of severe eating disorders, Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today announced that it will double its patient capacity, expanding its inpatient facilities from 12 beds to 24.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

2009 Mini-Psych School Program dispels myths surrounding mental illness

The Mental Illness Awareness Week is coming up, from October 4 to 10. On this occasion, Joseph Rochford, Ph.D., Director of the Academic Affairs at the Douglas Mental Health University Institute, presents his top ten list of myths about mental illness.

29 Sep 2009

Behavioral hospital receives Champion in Health Care award

Eating Recovery Center (www.eatingrecoverycenter.com), the only behavioral hospital in Colorado focused on comprehensive and sustainable treatment of eating disorders, was honored as a "Champion in Health Care" by the Denver Business Journal at the newspaper's annual awards ceremony last night.

26 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009